Tech Company Financing Transactions
Nuvation Bio Funding Round
Nuvation Bio closed a $275 million Series A funding round on 10/30/2019. Backers included Omega Funds, Aisling Capital and Altitude Life Science Ventures.
Transaction Overview
Company Name
Announced On
10/30/2019
Transaction Type
Venture Equity
Amount
$275,000,000
Round
Series A
Investors
Proceeds Purpose
The Series A financing will enable Nuvation Bio to expand its development activities and advance a number of its oncology programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1500 Bdwy. 1401
New York, NY 10036
USA
New York, NY 10036
USA
Phone
Undisclosed
Website
Email Address
Overview
Nuvation Bio, is a privately-held biopharmaceutical company currently operating in stealth mode that is focused on the development of next generation therapies that will target the foremost unmet needs in oncology. Nuvation Bio's proprietary portfolio includes seven novel and mechanistically distinct oncology programs, each with multiple drug development candidates.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Hung
Chief Medical Officer
Sergey Yurasov
Chief Scientific Officer
Gary Hattersley
VP - Human Resources
Stacy Markel
VP - Operations
Thomas Templeman
Browse more venture capital transactions:
Prev: 10/30/2019: Grax venture capital transaction
Next: 10/30/2019: Socially Determined venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs